Skip Navigation

This Article
Right arrow Abstract Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Disclaimer
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Julius, S.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Julius, S.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?


Bringing VALUE to LIFE

S. Julius*

Division of Hypertension and Hyperlipidemia, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, U.S.A.

* S. Julius, Division of Hypertension and Hyperlipidemia, Department of Internal Medicine, University of Michigan, Ann Arbor, MI 48109-0356, U.S.A.

Abstract

The results of the LIFE (Losartan Intervention for Endpoint Reduction) trial were the first demonstration that there are differences in outcomes between antihypertensive medications, beyond the reduction in blood pressure. For the first time, a ‘new’ antihypertensive medication, an angiotensin-receptor blocker (ARB) was shown to be superior over an ‘old’ drug, a beta blocker. However, there are questions remaining after LIFE, such as: was the reduction in stroke specific to ARBs? Why were there no greater reductions in cardiovascular mortality? What is the role of monotherapy versus a combination of ARB and a diuretic? Answers to several of these and other questions are expected from the VALUE (Valsartan Antihypertensive Long-term Use Evaluation) trial.

Key Words: Angiotensin receptor blocker • antihypertensive drugs • cardiovascular risk

References

  1. Dahlöf B, Devereux R, Kjeldsen S, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359:995–1003[CrossRef][Web of Science][Medline]
  2. Hansson L, Lindholm LH, Niskanen L, et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet. 1999;353:611–616[CrossRef][Web of Science][Medline]
  3. Hansson L, Lindholm LH, Ekbom T, et al. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. Lancet. 1999;354:1751–1756[CrossRef][Web of Science][Medline]
  4. Hansson L, Hedner T, Lund-Johansen P, et al. Randomised trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. Lancet. 2000;356:359–365[CrossRef][Web of Science][Medline]
  5. Brown MJ, Palmer CR, Castaigne A, et al. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet. 2000;356:366–372[CrossRef][Web of Science][Medline]
  6. ALLHAT collaborative Research Group. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA. 2000;283:1967–1975[Abstract/Free Full Text]
  7. Kjeldsen SE, Westheim AS, Os I. INSIGHT and NORDIL. International Nifedipine GITS study: intevention as a goal in hypertension treatment. Nordic Diltiazem Study. Lancet. 2000;356:1929–1930[Web of Science][Medline]
  8. Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000;342:145–153[Abstract/Free Full Text]
  9. Svensson P, de Faire U, Sleight P, Yusuf S, Ostergren J. Comparative effects of ramipril on ambulatory and office blood pressures: a HOPE Substudy. Hypertension. 2001;38:E28–E32
  10. Lindholm L, Ibsen H, Dahlöf B, et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;369:1004–1010
  11. Schiffrin EL, Park JB, Intengan HD, Touyz RM. Correction of arterial structure and endothelial dysfunction in human essential hypertension by the angiotensin receptor antagonist losartan. Circulation. 2000;101:1653–1659[Abstract/Free Full Text]
  12. Tzemos N, Lim P, McDonald TM. Valsartan improves vascular endothelial dysfunction in essential hypertension. [abstract]Am J Hypertens. 2001;14:66A
  13. Hansson L, Lithell H. The study on cognition and prognosis in elderly hypertensives (SCOPE). Prague, Czech Republic, June 23–27Data presented at the 19th Scientific Meeting of the International Society of Hypertension and 12th European Meeting on Hypertension — European Society of Hypertension. 2002.
  14. Thürmann PA, Kenedi P, Schmidt A, Harder S, Rietbrock N. Influence of the angiotensin II antagonist valsartan on left ventricular hypertrophy in patients with essential hypertension. Circulation. 1998;98:2037–2042[Abstract/Free Full Text]
  15. Motwani JG. Combining renin-angiotensin-aldosterone system blockade with diuretic therapy for treatment of hypertension. J Renin Angiotensin Aldosterone Syst. 2002;3:72–78[Abstract/Free Full Text]
  16. Lindholm LH, Ibsen H, Borch-Johnsen K, et al. Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study. J Hypertens. 2002;20:1879–1886[CrossRef][Web of Science][Medline]
  17. Lithell HO. Insulin resistance and diabetes in the context of treatment of hypertension. Blood Press. 1998;(suppl 3):28–31
  18. Poirier L, Cleroux J, Nadeau A, Lacourciere Y. Effects of nebivolol and atenolol on insulin sensitivity and haemodynamics in hypertensive patients. J Hypertens. 2001;19:1429–1435[CrossRef][Web of Science][Medline]
  19. Mann J, Julius S. The Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial of cardiovascular events in hypertension. Rationale and design. Blood Press. 1998;7:176–183[CrossRef][Medline]
  20. Julius S. Long-term potential of angiotensin receptor blockade for cardiovascular protection in hypertension: the VALUE trial. Valsartan Antihypertensive Long-term Use Evaluation. Cardiology. 1999;91:8–13[Web of Science][Medline]
  21. Kjeldsen S, Julius S, Brunner H, et al. Characteristics of 15314 hypertensive patients at high coronary risk. The VALUE trial. Blood Press. 2001;10:83–91[CrossRef][Web of Science][Medline]
  22. Dahlöf B, Devereux RB, Julius S, et al. Characteristics of 9194 patients with left ventricular hypertrophy: the LIFE study. Losartan Intervention For Endpoint Reduction in Hypertension. Hypertension. 1998;32:989–997[Abstract/Free Full Text]
  23. Dahlöf B, Devereux R, de Faire U, et al. The Losartan Intervention For Endpoint reduction (LIFE) in Hypertension study: rationale, design, and methods. The LIFE Study Group. Am J Hypertens. 1997;10:705–713[CrossRef][Web of Science][Medline]
  24. Ligtenberg G, Blankestijn PJ, Oey PL, et al. Reduction of sympathetic hyperactivity by enalapril in patients with chronic renal failure. N Engl J Med. 1999;340:1321–1328[Abstract/Free Full Text]
  25. Kannel WB, Gagnon DR, Cupples LA. Epidemiology of sudden coronary death: population at risk. Can J Cardiol. 1990;6:439–444[Web of Science][Medline]
  26. Latini R, Masson S, Anand I, et al. Effect of valsartan on circulating brain natriuretic peptide and norepinephrine in symptomatic chronic heart failure: the Valsartan Heart Failure Trial (Val-HeFT). Circulation. 2002;106:2454–2458[Abstract/Free Full Text]

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?



This Article
Right arrow Abstract Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Disclaimer
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Julius, S.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Julius, S.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?